Healthcare Industry News: HSMN NewsFeed
News Release - August 25, 2021
Baylis Medical Announces First Clinical Case Using the VersaCross(R) Large Access Solution in CanadaTORONTO, Aug. 25, 2021 -- (Healthcare Sales & Marketing Network) - Baylis Medical announced today the first clinical use of the VersaCross® Large Access Solution in Canada, to perform a Left Atrial Appendage Closure (LAAC) procedure. The new solution includes the world's first 3-in-1 radiofrequency (RF) wire paired with a seamless shapeable dilator designed to optimize tissue dilation for large sheath procedures including LAAC, transcatheter mitral valve repair, RF ablation, and several emerging left sided therapies.
Dr. Jacqueline Saw, a leading Interventional Cardiologist in Vancouver, BC, Canada, performed the first Canadian in-human cases with use of the VersaCross Large Access Solution during a left atrial appendage closure procedure, using the Amplatzer™ Amulet™ Occluder by Abbott. Dr. Saw also successfully completed a LAAC procedure using the Boston Scientific WATCHMAN™ implant, with the new solution.
"When getting to the left atrium for my LAAC procedure, speed and simplicity are key. The new VersaCross Large Access Solution allows me to simplify and expedite the procedure for delivering a LAAC sheath into the LA," said Dr. Saw. "The seamless dilator design optimizes tissue dilation, making crossing the septum smooth like butter."
The new solution features a seamless large access transseptal dilator with a sleek profile and no dilator-sheath transition; the device optimizes tissue dilation for large sheath access at both the femoral vein and through the atrial septum. After dilation, the 0.035" RF wire is instantly deployed and facilitates seamless delivery of large bore therapeutic sheaths to the left atrial appendage.
The included 3-in-1 wire features Baylis' proprietary RF puncture technology. The electrode-tipped wire can easily start at the SVC, perform RF transseptal puncture, and act as an 0.035" exchange wire in the left atrium, without the need for device exchanges.
"Building upon the successful launch of the VersaCross RF Transseptal Solution, the VersaCross Large Access Solution continues to address emerging patient and physician needs specific to large sheath procedures," said John Hanley, Regional Vice President, Canada and Asia-Pacific at Baylis. "We believe the simplicity, efficiency, and ease of use of the VersaCross Large Access Solution will set a new standard of care across all large bore therapy procedures."
The addition of the VersaCross Large Access Solution enables the delivery of a broader range of therapy devices for electrophysiology and interventional cardiology procedures.
Join our priority list to stay up to date on the latest information, here.
About Baylis Medical
Baylis Medical is a leader in the development and commercialization of innovative medical devices in the fields of cardiology and spine. Headquartered in Canada, and with offices world-wide, our clinical solutions have been Improving the Lives of People Around the World for over 30 years. For more information, visit www.baylismedical.com and connect with us on Twitter, LinkedIn and Instagram.
PRM-00805 EN J-1,2 V-1 © Baylis Medical Company Inc., 2021. Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. VersaCross, Baylis Medical, and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries. Other trademarks are property of their respective owners. Patents pending and/or issued. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.
Products shown may not be approved in all jurisdictions.
Source: Baylis Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.